Abstract-In the present study, we demonstrate that lung microvascular endothelial cells express a Ca v 3.1 (␣ 1G ) T-type voltage-gated Ca 2ϩ channel, whereas lung macrovascular endothelial cells do not express voltage-gated Ca 2ϩ channels. Voltage-dependent activation indicates that the Ca v 3.1 T-type Ca 2ϩ current is shifted to a positive potential, at which maximum current activation is Ϫ10 mV; voltage-dependent conductance and inactivation properties suggest a "window current" in the range of Ϫ60 to Ϫ30 mV. Thrombin-induced transitions in membrane potential activate the Ca v 3.1 channel, resulting in a physiologically relevant rise in cytosolic Ca 2ϩ . Furthermore, activation of the Ca v 3.1 channel induces a procoagulant endothelial phenotype; eg, channel inhibition attenuates increased retention of sickled erythrocytes in the inflamed pulmonary circulation. We conclude that activation of the Ca v 3.1 channels selectively induces phenotypic changes in microvascular endothelial cells that mediate vaso-occlusion by sickled erythrocytes in the inflamed lung microcirculation. 
S
ickle cell anemia patients exhibit a chronic state of inflammation that increases endothelial cell expression of surface adhesive proteins. 1 Adherence of sickled erythrocytes to abnormally adhesive lung microvascular endothelium initiates vaso-occlusion and acute chest syndrome. [1] [2] [3] [4] [5] [6] Endothelial cell adhesion to sickled erythrocytes is mediated through vascular cell adhesion molecule 1, ␣ v ␤ 3 integrins, glycoproteins Ib, IX, and V, and CD36. 7 Such cell-cell interactions are promoted by the regulated secretion of von Willebrand factor (vWf) and lipid procoagulants from the endothelium. 7 Collectively, these processes provide a means by which endothelial cells rapidly and selectively alter the microenvironment of individual vascular beds and modulate the interrelated processes of coagulation, fibrinolysis, inflammation, and vaso-occlusion.
Although intracellular events that transduce this abnormally adhesive endothelial cell surface are incompletely understood, the importance of elevated cytosolic Ca 2ϩ ([Ca 2ϩ ] i ) has been clearly established. 8 -12 Thrombin and other G q -linked neurohumoral inflammatory agonists increase endothelial cell [Ca 2ϩ ] i , 13 sufficient to cause rapid vWf secretion and P-selectin upregulation. 8,9,14 -17 However, specific Ca 2ϩ entry pathways that mediate these effects are poorly understood, particularly in microvascular endothelial cells obtained from the prominent site of vaso-occlusion 18, 19 ; indeed, we have previously shown that G q -linked agonists activate distinct Ca 2ϩ signaling pathways in lung microvascular and macrovascular endothelium. 20 -22 Therefore, our present challenge is to identify a channel(s) that provides the Ca 2ϩ source needed to promote coagulation and vaso-occlusion.
Voltage-gated Ca 2ϩ channels trigger vesicular translocation in excitable cells, although endothelial cells are nonexcitable and are generally believed to lack the expression of voltagegated ion channels. 23 This perception may be partly due to the preponderance of studies that have used endothelial cells derived from conduit vessels; the expression of voltage-gated Ca 2ϩ channels has recently been characterized in both brain and adrenal capillary endothelium. 24, 25 The present study indicates that lung microvascular endothelial cells express a T-type voltage-gated Ca 2ϩ channel, whereas lung macrovascular (eg, pulmonary artery) endothelial cells do not express voltage-gated Ca 2ϩ channels. Importantly, G q -linked agonists cause an initial transient hyperpolarization and, subsequently, a large sustained depolarization in lung endothelial cells. 26 -28 Likewise, loss of shear stress and generation of reactive oxygen species during ischemia induce lung endothelial cell membrane depolarization. 29, 30 These changes in membrane potential could activate T-type Ca 2ϩ channels. We hypothesized that Ca 2ϩ entry through T-type Ca 2ϩ channels in lung microvascular endothelium is an important amplification step that promotes the local retention of sickled erythrocytes leading to vaso-occlusion.
Materials and Methods

Cell Culture
Rat pulmonary artery endothelial cells (PAECs) and pulmonary microvascular endothelial cells (PMVECs) were isolated, cultured, and purity-verified using a method previously described. 22 
Patch-Clamp Electrophysiology
Whole-cell macroscopic currents were recorded using an EPC-9 amplifier (HEKA Elektronik). Data were acquired with Pulse/ PulseFit software (HEKA) and filtered at 2.9 kHz. Voltagedependent currents were corrected for linear leak and residual capacitance using an online P/n subtraction paradigm. (The definition for the so-called P/n leak correction protocol is that in a voltage range, where voltage-dependent channels are not active, a scaleddown version of the pulse protocol is applied n times, and resulting current is averaged, scaled, and subtracted from that elicited by the main test pulse.) Extracellular (bath) solution contained (mmol/L) CaCl 2 10, tetraethylammonium chloride 110, CsCl 10, and HEPES 10 (pH 7.4, adjusted with tetraethylammonium hydroxide). Intracellular (pipette) solution contained (mmol/L) N-methyl-D-glucamine 130, EGTA 10, BAPTA 5, HEPES 10, MgCl 2 6, CaCl 2 4, and Mg-ATP 2 (pH 7.2, adjusted with methane sulfonic acid). All solutions were adjusted to 290 to 300 mOsm with sucrose. Various drug dilutions were applied to cells by a gravity-driven perfusion device, operated by a perfusion valve controller (model VC-6, Warner Instrument).
Molecular Biology
Total RNA was extracted with RNA Stat-60 (Tel-Test "B") from cells grown to 100% confluence (10 7 cells) in 75-cm 2 tissue culture flasks. First-strand synthesis was performed with reverse transcriptase and oligo(dT) primer (Invitrogen) on 1 g DNase I-treated total RNA. Polymerase chain reaction (PCR) was then performed with the following sets of primers: Ca v 3.1, 5Ј-CATTTGCTGTGCC-TTCTTCA-3Ј (sense) and 5Ј-ATCCACACCCACAGCATCCAG-3Ј (antisense); Ca v 3.2, 5Ј-TGAATTCACGCAGGACGT-3Ј (sense) and 5Ј-CAGCTGTGCACATGATGA-3Ј (antisense). PCR products were ligated into TA cloning vector pCR2.1 (Invitrogen) and transformed into chemically competent Escherichia coli. Positive clones (verified by PCR analysis) were selected and grown in Luria-Bertani broth (Sigma) with kanamycin (50 g/mL) for 18 to 20 hours at 37°C. Plasmids were isolated by the QIAprep Spinprep system (QIAGEN) and submitted to the Biopolymer Laboratory at the University of South Alabama for automated fluorescence sequence analysis (AB373XL DNA stretch sequencer). Sequencing of both strands using double-stranded plasmids as templates and universal primers confirmed the product accuracy. Nucleotide and amino acid alignments were achieved with BLAST (National Center for Biotechnology Information, Bethesda, Md) and DNASIS v2.0 (Hitachi Software Engineering America) programs.
Cytosolic Ca
2؉ Measurements [Ca 2ϩ ] i was estimated in confluent PAECs and PMVECs using fura 2-AM (Molecular Probes). Calculations of free [Ca 2ϩ ] i are routinely made using modifications of the formula described by Grynkiewicz et al 31 Blood collection and blood cell preparations were performed as described previously. 32 The activation of polymorphonuclear cells (PMNs) was achieved in the test tube by the addition of phorbol myristate acetate (20 ng/mL) to PMNs suspended in 1 mL HBSS.
Isolated Perfused Lung and Erythrocyte Retention Assay
Isolated perfused lung and erythrocyte retention assays were performed as described by Haynes et al. 32 In the study using mibefradil (Hoffmann-La Roche), pimozide, or flunarizine, lungs were incubated with mibefradil (20 mol/L), pimozide (10 mol/L), and flunarizine (10 mol/L) for 30 minutes and then perfused to eliminate contact of the drug with circulating cells. Activated PMNs were subsequently added to the perfusate reservoir (Ϸ200 000/mL). Lungs were perfused in a recirculating fashion for 30 minutes, and the sickled erythrocyte retention/adherence was determined as previously described. 32 
Data Analysis
Numerical data are reported as meanϮSEM. A value of PϽ0.05 was considered significant.
Results
PMVECs Possess a T-Type Ca 2؉ Channel
Using a conventional whole-cell configuration of patchclamp recordings, we examined functional expression of T-type Ca 2ϩ channels in cultured rat PMVECs and PAECs. With Ca 2ϩ (10 mmol/L) as a charge carrier, we recorded that membrane depolarization of PMVECs produced transient robust Ca 2ϩ currents that were insensitive to high tetrodotoxin concentrations (data not shown). The current exhibited a low threshold of activation and inactivated quickly during depolarization voltage steps ( Figure 1A ). Analysis of currentvoltage (I-V) relationships in PMVECs ( Figure 1B ) revealed that these currents were consistently activated at ϷϪ60 mV; maximum current activation was observed at Ϫ10 mV ( Figure 1B ). Currents were typical of T-type Ca 2ϩ channels. Despite repeated efforts, we did not observe a voltagedependent Ca 2ϩ current in PAECs ( Figures 1A and 1B ).
Molecular Characterization of PMVEC T-Type Voltage-Gated Ca 2؉ Channels
We next examined whether the T-type Ca 2ϩ channel expressed in PMVECs was encoded by one of three known members of the T-channel family identified in neurons, cardiomyocytes, and pancreatic ␤-cells, namely, Ca v 3.1 (␣ 1G ), Ca v 3.2 (␣ 1H ), and Ca v 3.3 (␣ 1I ), respectively. [33] [34] [35] [36] Among the three subtypes of T-type Ca 2ϩ channels, Ca v 3.3 has been T-type Ca 2ϩ currents in PMVECs. Ca 2ϩ (10 mmol/L) was used as a charge carrier. A, Currents evoked in PMVECs by increasing depolarization from Ϫ70 to 60 mV with 10-mV increments from a holding potential of Ϫ90 mV. Arrow indicates peak current recorded at test pulse to Ϫ10 mV. Note crisscrossing pattern of current traces. 37 No currents were evoked in PAECs using the same protocol. B, Averaged I-V relationship of peak currents obtained from 55 PMVECs (solid squares) and 20 PAECs (open squares).
described only in neurons, and it possesses a slower voltagedependent activation and inactivation compared with other T-channel types 35 and with the PMVEC current ( Figure 1A ). Therefore, it is likely that the PMVEC current is mediated by either Ca v 3.1, Ca v 3.2, or both channels. Total RNA isolated from PMVECs and PAECs was amplified using sequencespecific primers designed to target Ca v 3.1 and Ca v 3.2 pore regions, respectively. A single Ca v 3.1 product of expected size was selectively amplified from PMVEC RNA ( Figure  2A ). Sequence analysis revealed that the cloned product was 100% homologous to the previously reported rat Ca v 3.1 subunit ( Figure 2B ). These data reveal that Ca v 3.1 subunits form functional T-type Ca 2ϩ channels in PMVECs. Reverse transcription (RT)-PCR analysis using sequence-specific
, and ␣ 1S (Ca v 1.1) (L-type) did not yield any product in PMVECs (data not shown).
Biophysical Characterization of PMVEC T-Type Ca 2؉ Channels
We characterized the gating properties of PMVEC Ca v 3.1 channels. Voltage dependence of channel activation was obtained from the above I-V relationships by calculating conductance from the equation G T ϭI T /(VϪV rev ), where I T is the current amplitude, V is the membrane potential, and V rev is the reversal potential for Ca 2ϩ (a value of 70 mV was used in our calculations). Normalized values of channel conductance were plotted as a function of the membrane potential 2ϩ (10 mmol/L) was used as a charge carrier. A, Normalized values of channel conductance were plotted as a function of the membrane potential (nϭ46). The smooth curve corresponds to the best fit obtained using the described Boltzmann equation G/G max ϭ1/{1ϩexp[(VϪV 1/2 )/k]}. B, Steadystate inactivation was estimated from measurement of the current amplitude at Ϫ20 mV after a 1500-ms predepolarization pulse of increasing amplitude (Ϫ80 to Ϫ20 mV, 5-mV increment). C, Normalized steady-state inactivation curve (nϭ12) was best fitted with the Boltzmann equation
The dashed curve represents the activation curve from panel A. Thus, a steady-state T current, referred to as a window current, is predicted by the overlap of the voltage range for activation and inactivation, Ϫ60 to Ϫ30 mV in PMVECs. D and E, Determination of the steady-state activation was based on the measurement of tail-current amplitudes. Physiological Ca 2ϩ (2 mmol/L) was used as a charge carrier. Currents were evoked by depolarizations from Ϫ70 to 80 mV, followed by a 20-ms repolarization to the potential of Ϫ120 mV. For each depolarization, the tail-current amplitude was measured for pulse durations adjusted from the membrane potential/time-to-peak plot shown in panel D. Panel E shows representative fully activated PMVEC T-type Ca 2ϩ current tail traces at various depolarizing pulses. F, Normalized steady-state activation obtained from the protocol described in panel A is shown (closed circles, nϭ6). The smooth curve corresponds to the best fit obtained using the Boltzmann equation, with I/I max being a function of the test potential (V) according to the equation I/I max ϭ1/{1ϩexp[(VϪV 1/2 )/k]}, and halfactivation potential (V 1/2 ) of Ϫ30.8 mV and a slope (k) of 13.2. The dashed and dash-dotted curves represent activation and inactivation curves, respectively, from panels A and C (10 mmol/L Ca 2ϩ ). Thus, a predicted window-current range of voltages near Ϫ60 to Ϫ30 mV in physiological conditions has been confirmed in PMVECs. ( Figure 3A) . The steady-state inactivation properties were characterized by applying a standard double-pulse protocol (ie, a 1500-ms prepulse from Ϫ80 to Ϫ20 mV with 5-mV increments, followed by a 100-ms test pulse at Ϫ20 mV). The currents were measured at Ϫ20 mV after varying 1500-ms prepulse potentials ( Figure 3B ). Peak currents were normalized to maximum current and then plotted as a function of the prepulse potential ( Figure 3C ). Both activation and inactivation were fitted with a Boltzmann equation of the form G/G max or I/I max ϭ1/{1ϩexp[(VϪV 1/2 )/k]}, where V is the membrane potential (for activation) or prepulse potential (for inactivation), V 1/2 is the voltage at which activation or inactivation is half maximal, and k is the slope factor. For activation and inactivation, the calculated V 1/2 values were Ϫ28.4 and Ϫ51.4 mV, respectively, and k values were 7.084 and Ϫ5.556, respectively. Superimposition of activation and inactivation curves predicted a "window current" in the range of Ϫ60 to Ϫ30 mV ( Figure 3C ). To confirm that such a window-current range of voltages occurs in physiological conditions, the voltage dependence of the channel activation was determined for a second time in 2 mmol/L extracellular Ca 2ϩ by measuring T tail-current amplitudes at various depolarizing pulses ( Figure 3E ) that fully activate Ca v 3.1 currents, with duration of each pulse adjusted to the average time-to-peak current values ( Figure 3D ). Normalized tail-current amplitudes were plotted as a function of the membrane potential and fitted using the Boltzmann equation with V 1/2 ϭϪ30.8 mV, virtually identical to the activation curve obtained in 10 mmol/L Ca 2ϩ ( Figure 3F ).
We characterized deactivation properties of PMVEC Ca v 3.1 channels from tail-current analysis ( Figures 4A and  4B ). Ca v 3.1 currents were activated by a transition from a holding potential of Ϫ90 to Ϫ10 mV for 7 ms, and a family of tail currents was recorded for subsequent repolarization from Ϫ120 to Ϫ20 mV. Tail currents were fitted with a single exponential. The rate of deactivation, which reflects the rate of channel closing after removal of membrane depolarization, was measured as the rate of decay of tail currents at different repolarization potentials, named deactivation time constants (), and plotted as a function of membrane repolarization potential. The tail-current kinetics were slower when membrane repolarization potential was more positive. Deactivation time constants increased by e-fold per 31.3 mV of repolarization, reflecting strong voltage dependence of the deactivation process for Ca v 3.1 currents ( Figure 4B ). 37 
Pharmacological Characterization of PMVEC T-Type Ca 2؉ Channels
We examined sensitivity of PMVEC T-type Ca 2ϩ channels to inhibition by Ni 2ϩ and four molecules (mibefradil, kurtoxin, A, Representative PMVEC T-type Ca 2ϩ current tail traces. Currents were evoked using the following voltage protocol: a 7-ms step to Ϫ10 mV, followed by repolarization to potentials from Ϫ120 to Ϫ20 mV with 10-mV increment. B, Plot of mean deactivation time constant () as a function of membrane repolarization potentials (nϭ6). Smooth curve represents exponential function of repolarization potential (e-fold per 31.3 mV).
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pimozide, and flunarizine, which are all considered T-type channel blockers) ( Figure 5 ). We used a T-tail current to measure peak Ca 2ϩ current amplitude and to obtain the precise concentration of Ni 2ϩ required to inhibit the PMVEC current. Ni 2ϩ weakly inhibited the PMVEC T current (IC 50 380.25 mol/L), characteristic of the Ca v 3.1 and not Ca v 3.2 subtype of T channels. 38 Despite the insensitivity of the endogenous PMVEC Ca v 3.1 channel to Ni 2ϩ blockade, we found inhibition using mibefradil, a benzimidazolylsubstituted tetraline derivative, considered one of the most potent T-type channel blockers, 39 in good agreement with previous studies on recombinant Ca v 3.1 T-type channels. 40, 41 In similar experiments, we also observed inhibition of PM-VEC T currents by kurtoxin (Peptides International, Inc), pimozide, and flunarizine. Kurtoxin is a newly identified scorpion toxin that binds to the Ca v 3.1 channel with high affinity and distinguishes between Ca v 3.1 and other types of voltage-gated Ca 2ϩ channels, including Ca v 2.1 (␣ 1A , P/Qtype), Ca v 2.2 (␣ 1B , N-type), Ca v 1.2 (␣ 1C , L-type), and Ca v 2.2 (␣ 1E , R-type), 42 whereas a diphenylbutylpiperidine antipsychotic drug, pimozide, and a diphenyldiperazine derivative, flunarizine, have both been shown to be potent T-type channel blockers. 43 
T-Type Ca 2؉ Channel Contributes to Thrombin or Thapsigargin-Induced Ca 2؉ Entry in PMVECs
Physiological activation of T-type Ca 2ϩ channels occurs when the membrane potential shifts into the window-current range, which is Ϫ60 to Ϫ30 mV in PMVECs. Importantly, G qlinked neurohumoral inflammatory agonists cause an initial transient hyperpolarization and, subsequently, a large sustained depolarization in lung endothelial cells. 26 -28 This subsequent depolarizing current is of sufficient magnitude to shift the membrane potential to the T-channel window current range of voltages, suggesting that thrombin and other G qlinked inflammatory agonists would activate the PMVEC T channel.
Prior studies in nonexcitable cells, such as endothelia, have established that the principal mode of Ca 2ϩ entry across the plasmalemma is through so-called store-operated Ca 2ϩ entry channels. 23 We have recently examined store-operated Ca 2ϩ entry pathways in PMVECs and PAECs and have observed that the magnitudes of Ca 2ϩ release and entry are not associated between these cell types. 22 Therefore, it is conceivable that PMVECs possess novel Ca 2ϩ entry mechanisms that are distinct from store-operated Ca 2ϩ entry pathways. To evaluate the contribution of Ca v 3.1 T currents to agonistinduced rises in [Ca 2ϩ ] i , we inhibited the Ca v 3.1 channels using mibefradil (10 mol/L, IC 100 ) and then applied thrombin (10 U/mL, G q -linked agonist) or thapsigargin (1 mol/L, direct activation of store-operated Ca 2ϩ entry). Mibefradil reduced the thrombin-and thapsigargin-induced increase in [Ca 2ϩ ] i ( Figures 6A and 6B ), indicating that activation of store-operated Ca 2ϩ entry also results in Ca 2ϩ permeation through Ca v 3.1 channels in PMVECs. To ensure that these results were due to the activation of T channels after a physiological transition into the window-current range of voltages and not due to nonspecific actions of mibefradil, studies were repeated in low extracellular Ca 2ϩ . This protocol is commonly used to examine the magnitude of Ca 2ϩ release and to discriminate between Ca 2ϩ release and Ca 2ϩ entry components of the global [Ca 2ϩ ] i response. As seen in Figure  6C , mibefradil (IC 100 ) did not reduce thapsigargin-stimulated Ca 2ϩ release in PMVECs ( Figure 6C ), indicating that T-channel inhibition does not disrupt store-operated Ca 2ϩ entry pathways. Furthermore, mibefradil did not decrease the thrombin-induced Ca 2ϩ response in PAECs ( Figure 6D ), which lack expression of T channels. Thus, G q -linked agonists directly activate Ca 2ϩ entry through Ca v 3.1 channels in PMVECs. 
Ca v 3.1 T-Type Ca 2؉ Channels Contribute to Sickled Erythrocyte Retention in Lung Microcirculation
Recently, Haynes et al 32 developed a lung inflammation model to investigate sickled erythrocyte retention in the intact pulmonary circulation. They found that activated PMNs promoted sickled erythrocyte retention in an isolated perfused lung preparation. The combination of platelet activating factor and leukotriene B 4 increased sickled erythrocyte retention, and a 5-lipoxygenase inhibitor (zileuton) attenuated sickled erythrocyte retention. Their findings suggest that neurohumoral inflammatory mediators promote the adhesion of sickled erythrocytes to endothelial cells.
Many inflammatory mediators released from PMNs stimulate receptor-G q -linked pathways and may therefore consolidate to activate T channels within the lung microvasculature necessary for vaso-occlusion. Using the model developed by Haynes et al, 32 we examined whether Ca v 3.1 channels contribute to sickled erythrocyte retention. Sickled erythrocytes (5.8Ϯ0.1ϫ10 8 /g) were retained in the inflamed lung circulation (nϭ12). Lung pretreatment with mibefradil (20 mol/L) for 30 minutes completely abolished the effect of activated PMNs on sickled erythrocyte retention (Figure 7) . Similarly, pimozide and flunarizine abolished the PMN-induced lung sickle cell retention. These findings indicate that vasoocclusion proceeds in the inflamed lung via a mechanism that involves the T-type Ca 2ϩ channel.
Discussion
Developmental studies indicate that lung conduit vessels arise from angiogenesis, whereas the microcirculation arises from vasculogenesis, 44 suggesting that macrovascular and microvascular endothelial cells arise from embryologically distinct origins. Such heterogeneity has been illustrated in Ca 2ϩ -dependent signal transduction pathways. 20, 22 In the present study, we demonstrate the selective expression of Ca v 3. channel. An important property of T-type Ca 2ϩ channels is that they display window currents. That is, there is a voltage range at which channels do not completely inactivate; therefore, they conduct Ca 2ϩ . This property is commonly defined by the presence of an overlap region between the steady-state inactivation and activation curves. T-type window currents play an important role in regulating a variety of cellular functions, including neuronal excitability, 45 ␤-cell secretion, 46 and myoblast terminal differentiation. 47 We examined voltage-dependent activation and inactivation kinetics of the PMVEC T-type Ca 2ϩ channels. Superimposition of voltagedependent activation and inactivation curves of T-type Ca 2ϩ currents reveals a window current in the range of Ϫ60 to Ϫ30 mV. This PMVEC T-type window-current region is expanded compared with that of native Ca v 3.1 channels expressed in HEK-293 cells (Ϫ65 to Ϫ55 mV) 48 and with that of endogenous Ca v 3.1 channels in cardiac myocytes (Ϫ65 to Ϫ45 mV). 49 This expanded T-type window current is due to a right-shifted steady-state inactivation curve, which suggests that more channels are available to open. The expanded window current together with the right-shifted I-V relationship appears to represent a unique physiological relevance of Ca v 3.1 channels in PMVECs. The T-type window range is very close to the resting membrane potential of many endothelial cells (Ϫ70 to Ϫ60 mV or Ϫ40 to Ϫ10 mV). Thus, small depolarizing currents shift the membrane potential into the window-current range of voltages, which is important to sustain physiologically relevant Ca 2ϩ entry. In endothelial cells, the [Ca 2ϩ ] i response to G q -linked agonists is broadly characterized by Ca 2ϩ release from intracellular stores and Ca 2ϩ entry across the cell membrane after Ca 2ϩ store depletion, which are due to the activation of store-operated and receptor-operated Ca 2ϩ channels, which are thought to represent the principal Ca 2ϩ entry pathways. 50 However, data shown in the present study resolve another mechanism of Ca 2ϩ entry, eg, Ca 2ϩ entry through Ca v 3.1 T-type Ca 2ϩ channels within the window-current range of voltages. Indeed, mibefradil dramatically reduced thrombinand thapsigargin-stimulated Ca 2ϩ entry in PMVECs without affecting Ca 2ϩ release. We exclude other "nonspecific" effects of mibefradil that could occur at its IC 100 dose, because mibefradil is without effect in PAECs, which possess storeoperated Ca 2ϩ entry pathways but do not possess T channels. Thus, thrombin depolarizes the PMVEC membrane potential into a window-current range, which is sufficient to activate Ca v 3.1 channels.
In our isolated perfused lung model, inhibition of T-type Ca 2ϩ channels completely abolished the increased retention of sickled erythrocytes in the inflamed pulmonary circulation. These findings suggest that platelet-activating factor, leukotriene B 4 , and likely other inflammatory agonists consolidate their PMVEC actions by signaling through Ca v 3.1 channels. Thus, Ca 2ϩ -dependent phenotypic changes in microvascular endothelial cells, ie, stimulated secretion of multimeric vWf 
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and upregulation of adhesion molecules, mediate vasoocclusion of sickled erythrocytes in the lung microcirculation through Ca v 3.1 channels. Taken together, our observations support a novel potential therapeutic strategy using selective T-type Ca 2ϩ channel antagonists for the prevention of vaso-occlusive crisis in sickle cell anemia or even for the treatment of thrombotic disorders. Although current antithrombotic therapy involves the use of thrombolytic, antiplatelet, and anticoagulant agents, none of these drugs targets endothelial cells with the procoagulant phenotypic changes necessary for triggering the extrinsic pathway of coagulation. Thus, a specific T-type Ca 2ϩ channel antagonist may provide broadly ranging anticoagulant activity and have therapeutic utility in microvascular thromboembolic disorders of various etiologies in the cardiovascular, pulmonary, and hematological systems.
